TRIHEXYPHENIDYL HYDROCHLORIDE 5 mg Tablet, 1,000-count
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Tertiary amines class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Trihexyphenidyl is used along with other medications to treat the symptoms of Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance) and to control extrapyramidal symptoms (tremor, slurred speech) caused by certain medications. Trihexyphenidyl is in a class of medications called antimuscarinics. It works by relaxing muscles and nerve impulses that control the function of muscles.
Read the full MedlinePlus article ↗- Trihexyphenidyl is mainly used to treat parkinsonism — whether it developed on its own, after a brain infection, or from narrowing of blood vessels. It's often added to levodopa wh...
- What is trihexyphenidyl actually used for?
- It depends on how your body reacts. If it makes your mouth very dry, taking it before meals can help. If it causes nausea, take it after meals. If after-meal thirst is a problem, s...
- Should I take it before or after eating?
Patient education
Supplement & herbal interactions
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Where does this data come from?
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII OP1R32D61U
Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
-
UNII 5856J3G2A2
A starch-based powder made from potatoes and processed with sodium. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the medicine can be absorbed.
3 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.120 | $120.30 / 1000 tablets |
| Medicaid paysCMS SDUD · 12 mo | $0.2646 | $264.60 / 1000 tablets |
| Medicare drug plans payPart D · Q2 2026 | $0.2046 | $204.60 / 1000 tablets |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Trihexyphenidyl Hydrochloride 5 mg 00591-5337-01 | Actavis | 100 tablets | $0.120 | — | Availability likely | — |
| Trihexyphenidyl Hydrochloride 5 mgthis 70954-0211-20 | Novitium | 1000 tablets | $0.120 | AA | Availability likely | — |
| Trihexyphenidyl Hydrochloride 5 mg 51407-0266-01 | Golden | 100 tablets | — | AA | FDA listed | — |
| Trihexyphenidyl Hydrochloride 5 mg 63850-0022-01 | Natco | 100 tablets | — | AA | FDA listed | — |
| Trihexyphenidyl Hydrochloride 5 mg 70518-1140-00 | REMEDYREPACK | 30 tablets | — | AA | FDA listed | — |
| Trihexyphenidyl Hydrochloride 5 mg 70518-1657-01 | REMEDYREPACK | 100 tablets | — | AA | FDA listed | — |
| Trihexyphenidyl Hydrochloride 5 mg 70518-2409-02 | REMEDYREPACK | 100 tablets | — | AA | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🗺️ Medicaid utilization & spend
💊 Medicaid utilization by pack size
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 70954-0211-10 | 100 TABLET in 1 BOTTLE (70954-211-10) | $0.1203 / ea | $12.03 | 2019-01-28 | Active |
| 70954-0211-20 You're viewing this | 1000 TABLET in 1 BOTTLE (70954-211-20) | $0.1203 / ea | $120.34 | 2019-01-28 | Active |
You're viewing the largest of 2 pack sizes for this product.
This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($0.1203 NADAC).
This pack accounts for about 13% of this product's recent Medicaid fills; most go to the 100 tablets pack. See all packs ↓
Pack size FAQ
What quantity is in NDC 70954-0211-20?
What is the difference between NDC 70954-0211-20 and NDC 70954-0211-10?
What NDC number is used to bill for this package of TRIHEXYPHENIDYL HYDROCHLORIDE 5 mg Tablet?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS & USAGE This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones.
⏱️ Dosage and Administration ▾
DOSAGE & ADMINISTRATION Dosage should be individualized. The initial dose should be low and then increased gradually, especially in patients over 60 years of age. Whether trihexyphenidyl hydrochloride may best be given before or after meals should be determined by the way the patient reacts.
Postencephalitic patients, who are usually more prone to excessive salivation, may prefer to take it after meals and may, in addition, require small amounts of atropine which, under such circumstances, is sometimes an effective adjuvant. If trihexyphenidyl hydrochloride tends to dry the mouth excessively, it may be better to take it before meals, unless it causes nausea. If taken after meals, the thirst sometimes induced can be allayed by mint candies, chewing gum or water.
Trihexyphenidyl Hydrochloride in Idiopathic Parkinsonism As initial therapy for parkinsonism, 1 mg may be administered the first day. The dose may then be increased by 2 mg increments at intervals of three to five days, until a total of 6 to 10 mg is given daily. The total daily dose will depend upon what is found to be the optimal level.
Many patients derive maximum benefit from this daily total of 6 to 10 mg, but some patients, chiefly those in the postencephalitic group, may require a total daily dose of 12 to 15 mg. Trihexyphenidyl Hydrochloride in Drug-Induced Parkinsonism The size and frequency of dose of trihexyphenidyl hydrochloride needed to control extrapyramidal reactions to commonly employed tranquilizers, notably the phenothiazines, thioxanthenes, and butyrophenones, must be determined empirically. The total daily dosage usually ranges between 5 and 15 mg, although, in some cases, these reactions have been satisfactorily controlled on as little as 1 mg daily.
It may be advisable to commence therapy with a single 1 mg dose. If the extrapyramidal manifestations are not controlled in a few hours, the subsequent doses may be progressively increased until satisfactory control is achieved. Satisfactory control may sometimes be more rapidly achieved by temporarily reducing the dosage of the tranquilizer on instituting trihexyphenidyl hydrochloride therapy and then adjusting dosage of both drugs until the desired ataractic effect is retained without onset of extrapyramidal reactions.
It is sometimes possible to maintain the patient on a reduced trihexyphenidyl hydrochloride dosage after the reactions have remained under control for several days. Instances have been reported in which these reactions have remained in remission for long periods after trihexyphenidyl hydrochloride therapy was discontinued. Concomitant Use of Trihexyphenidyl Hydrochloride with Levodopa When trihexyphenidyl hydrochloride is used concomitantly with levodopa, the usual dose of each may need to be reduced.
Careful adjustment is necessary, depending on side effects and degree of symptom control. Trihexyphenidyl hydrochloride dosage of 3 to 6 mg daily, in divided doses, is usually adequate. Concomitant Use of Trihexyphenidyl Hydrochloride with Other Parasympathetic Inhibitors Trihexyphenidyl Hydrochloride may be substituted, in whole or in part, for other parasympathetic inhibitors.
The usual technique is partial substitution initially, with progressive reduction in the other medication as the dose of trihexyphenidyl hydrochloride is increased. Trihexyphenidyl Hydrochloride Tablets - The total daily intake of trihexyphenidyl hydrochloride tablets is tolerated best if divided into 3 doses and taken at mealtimes. High doses (> 10 mg daily) may be divided into 4 parts, with 3 doses administered at meal times and the fourth at bedtime.
⚠️ Warnings ▾
WARNINGS Patients to be treated with trihexyphenidyl hydrochloride should have a gonioscope evaluation and close monitoring of intraocular pressures at regular periodic intervals.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Minor side effects, such as dryness of the mouth, blurring of vision, dizziness, mild nausea, or nervousness, will be experienced by 30 to 50 percent of all patients. These sensations, however, are much less troublesome with trihexyphenidyl hydrochloride than with belladonna alkaloids and are usually less disturbing than unalleviated parkinsonism. Such reactions tend to become less pronounced, and even to disappear, as treatment continues.
Even before these reactions have remitted spontaneously, they may often be controlled by careful adjustment of the dosage form, amount of drug, or interval between doses. Isolated instances of suppurative parotitis secondary to excessive dryness of the mouth, skin rashes, dilatation of the colon, paralytic ileus, and certain psychiatric manifestations such as delusions and hallucinations, plus one doubtful case of paranoia all of which may occur with any of the atropine-like drugs, have been rarely reported with trihexyphenidyl hydrochloride.
Patients with arteriosclerosis or with a history of idiosyncrasy to other drugs may exhibit reactions of mental confusion, agitation, disturbed behavior, or nausea and vomiting. Such patients should be allowed to develop a tolerance through the initial administration of a small dose and gradual increase in dose until an effective level is reached. If a severe reaction should occur, administration of the drug should be discontinued for a few days and then resumed at a lower dosage.
Psychiatric disturbances can result from indiscriminate use (leading to overdosage) to sustain continued euphoria. Potential side effects associated with the use of any atropine-like drugs include constipation, drowsiness, urinary hesitancy or retention, tachycardia, dilation of the pupil, increased intraocular tension, weakness, vomiting, and headache. The occurrence of angle-closure glaucoma due to long-term treatment with trihexyphenidyl hydrochloride has been reported.
To report SUSPECTED ADVERSE REACTIONS, contact Novitium Pharma LLC at 1-516-305-1658 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Trihexyphenidyl Hydrochloride is the substituted piperidine salt, 3-(1-piperidyl)- 1-phenylcyclohexyl-1-propanol hydrochloride, which exerts a direct inhibitory effect upon the parasympathetic nervous system. It also has a relaxing effect on smooth musculature; exerted both directly upon the muscle tissue itself and indirectly through an inhibitory effect upon the parasympathetic nervous system. Its therapeutic properties are similar to those of atropine, although undesirable side effects are ordinarily less frequent and severe than with the latter.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Trihexyphenidyl Hydrochloride Tablets, USP 2 mg are available as white, flat face, beveled edge and round. The upper layer is bisected and debossed "212/N" , the lower layer is plain: Bottle of 100’s NDC 70954-212-10 Bottle of 1000’s NDC 70954-212-20 Trihexyphenidyl Hydrochloride Tablets, USP 5 mg are available as white, flat face, beveled edge and round. The upper layer is bisected and debossed "211/N", the lower layer is plain: Bottle of 100’s NDC 70954-211-10 Bottle of 1000’s NDC 70954-211-20 Dispense in a tight container with child-resistant closure.
Store at 20° to 25° (68° to 77°F) [See USP Controlled Room Temperature]. Manufactured by: Novitium Pharma LLC, 70 Lake Drive, East Windsor, New Jersey-08520
📋 Description ▾
DESCRIPTION Trihexyphenidyl hydrochloride Tablets, USP is a synthetic antispasmodic drug available in the following forms: Tablets, 2 mg and 5 mg. It is designated chemically 1-Piperidinepropanol,α-cyclohexyl-α-phenyl-, hydrochloride. The structural formula is represented below: Trihexyphenidyl Hydrochloride Tablets, USP 2 mg and 5 mg contain the following inactive ingredients: Microcrystalline cellulose, magnesium stearate and sodium starch glycolate. structure